Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dengzhanxixin Capsule in individuals at high risk for cardiovascular disease
NCT05459519Unknown
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of Dengzhanxixin in atherosclerotic cardiovascular disease (ASCVD), sponsored by National Center for Cardiovascular Disease. Status: unknown.
02
Drugs
Dengzhanxixin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05459519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05459519.